EUVIMEDEUVIMED entdecken
Crossref

Medications and Risk for Microscopic Colitis: A Nationwide Study of Older Adults in Sweden

Hamed Khalili iD, Emma E McGee iD, Prasanna K Challa iD, Bjorn Roelstraete iD, Kristina Johnell, Sebastian Schneeweiss iD, Jonas W Wastesson iD, Jonas F Ludvigsson iD

Annals of Internal Medicine · 2025

DOI: 10.7326/annals-25-00268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2025. Verfasst von Hamed Khalili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Clinical and Translational Epidemiology Unit, M…. Hauptthemen laut MEDLINE: Colitis, Microscopic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Several medications have been identified as potential risk factors for microscopic colitis (MC), but evidence so far is hampered by methodological limitations. OBJECTIVE: To examine the potential causal effects of previously implicated medications on risk for MC. DESIGN: Emulation of 6 target trials. SETTING: Sweden. PARTICIPANTS: All residents in Sweden aged 65 years or older between 2006 and 2017 who met eligibility criteria (n = 191 482 to 2 634 777). MEASUREMENTS: The primary outcome was biopsy-verified MC. The date of diagnosis was obtained from the nationwide histopathology cohort ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden). Twelve- and 24-month cumulative incidences and absolute risk differences for MC were estimated via inverse probability weighing. RESULTS: The 12- and 24-month cumulative incidences of MC were less than 0.5% under all treatment strategies. Estimated 12-month risk differences were close to null under angiotensin-converting enzyme versus calcium-channel blocker (CCB) initiation, angiotensin-receptor blocker versus CCB initiation, nonsteroidal anti-inflammatory drug initiation versus noninitiation, proton-pump inhibitor initiation versus noninitiation, and statin initiation versus noninitiation. The estimated 12-month risk difference was 0.04% (95% CI, 0.03% to 0.05%) for selective serotonin receptor inhibitors (SSRIs) versus mirtazapine. Results were similar for 24-month risk differences. Several medications were also associated with increased risk for receiving a colonoscopy with a normal colorectal mucosa biopsy result. LIMITATIONS: There is possible residual bias due to differential health care utilization or surveillance. Lack of primary care data limited measurement of, and adjustment for, symptoms and medical diagnoses that increase risk for receiving a colonoscopy. CONCLUSION: No evidence of a causal relationship between most previously suspected pharmacologic triggers and risk for MC was found. Previously reported associations and persistent associations with SSRI initiation may be due to surveillance bias. PRIMARY FUNDING SOURCE: The National Institutes of Health and the Swedish Research Council.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, MicroscopicHumansAgedSwedenMaleFemaleRisk FactorsIncidenceAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAngiotensin-Converting Enzyme Inhibitors

Substanzen

Anti-Inflammatory Agents, Non-SteroidalAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Gastroenterology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Clinical and Translational Epidemiology Unit, Mongan Institute, Department of Medicine, Massachusetts General Hospita…
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts; and Department of Epidemiology, Harvard T.H Chan School of Public Health, Boston, Massachusetts (E.E.M.).
  • Clinical and Translational Epidemiology Unit, Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts (P.K.C.).
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (B.R., K.J., J.W.W.).
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts (S.S.).
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Orebro University Hospital, Orebro, Sweden; and Department of Medicine, Columbia University Colle…

ORCID-Profile: Hamed Khalili, Emma E McGee, Prasanna K Challa, Bjorn Roelstraete, Sebastian Schneeweiss, Jonas W Wastesson, Jonas F Ludvigsson

Förderung

  • NIA NIH HHS

Zitieren

APA

Khalili, H., McGee, E. E., Challa, P. K., Roelstraete, B., Johnell, K., Schneeweiss, S., Wastesson, J. W., & Ludvigsson, J. F. (2025). Medications and Risk for Microscopic Colitis: A Nationwide Study of Older Adults in Sweden. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-00268

Vancouver

Khalili H, McGee EE, Challa PK, Roelstraete B, Johnell K, Schneeweiss S, et al. Medications and Risk for Microscopic Colitis: A Nationwide Study of Older Adults in Sweden. Annals of Internal Medicine. 2025. doi:10.7326/annals-25-00268

BibTeX
@article{Khalili2025,
  author = {Khalili, Hamed and McGee, Emma E and Challa, Prasanna K and Roelstraete, Bjorn and Johnell, Kristina and Schneeweiss, Sebastian and Wastesson, Jonas W and Ludvigsson, Jonas F},
  title = {Medications and Risk for Microscopic Colitis: A Nationwide Study of Older Adults in Sweden},
  journal = {Annals of Internal Medicine},
  year = {2025},
  doi = {10.7326/annals-25-00268}
}
Kostenlos starten →